| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 49 | 2025 | 633 | 11.470 |
Why?
|
| Renal Insufficiency, Chronic | 32 | 2023 | 728 | 5.170 |
Why?
|
| Glomerular Filtration Rate | 29 | 2025 | 500 | 3.030 |
Why?
|
| Alberta | 40 | 2025 | 45 | 2.580 |
Why?
|
| Contrast Media | 8 | 2022 | 473 | 2.510 |
Why?
|
| Risk Assessment | 27 | 2025 | 3448 | 2.210 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2022 | 254 | 2.160 |
Why?
|
| Coronary Angiography | 7 | 2022 | 441 | 2.100 |
Why?
|
| Kidney Failure, Chronic | 16 | 2022 | 877 | 1.840 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2022 | 171 | 1.820 |
Why?
|
| Renal Replacement Therapy | 9 | 2025 | 142 | 1.770 |
Why?
|
| Renal Dialysis | 20 | 2023 | 852 | 1.750 |
Why?
|
| Postoperative Complications | 9 | 2025 | 3069 | 1.520 |
Why?
|
| Cardiac Catheterization | 6 | 2019 | 634 | 1.490 |
Why?
|
| Acute Coronary Syndrome | 5 | 2020 | 215 | 1.480 |
Why?
|
| Kidney Diseases | 10 | 2024 | 478 | 1.460 |
Why?
|
| Nephrology | 5 | 2022 | 146 | 1.300 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 1268 | 1.300 |
Why?
|
| Surgical Procedures, Operative | 3 | 2021 | 184 | 1.220 |
Why?
|
| Kidney | 13 | 2023 | 1356 | 1.210 |
Why?
|
| Aged | 62 | 2025 | 19825 | 1.100 |
Why?
|
| Cohort Studies | 32 | 2025 | 4805 | 1.060 |
Why?
|
| Creatinine | 14 | 2023 | 390 | 1.060 |
Why?
|
| Cardiovascular Diseases | 11 | 2024 | 1950 | 1.030 |
Why?
|
| Electronic Health Records | 3 | 2020 | 723 | 1.030 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 6583 | 1.020 |
Why?
|
| Hospitalization | 17 | 2020 | 1780 | 1.000 |
Why?
|
| Middle Aged | 62 | 2025 | 26867 | 0.990 |
Why?
|
| Risk Factors | 33 | 2023 | 10281 | 0.980 |
Why?
|
| Humans | 117 | 2025 | 124867 | 0.970 |
Why?
|
| Male | 76 | 2025 | 61375 | 0.870 |
Why?
|
| Models, Biological | 3 | 2019 | 1458 | 0.870 |
Why?
|
| Female | 77 | 2025 | 66655 | 0.840 |
Why?
|
| Cause of Death | 6 | 2020 | 474 | 0.830 |
Why?
|
| Proteinuria | 6 | 2018 | 101 | 0.820 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 46 | 0.810 |
Why?
|
| Prognosis | 18 | 2023 | 4631 | 0.810 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 1115 | 0.800 |
Why?
|
| Medical Audit | 1 | 2022 | 103 | 0.770 |
Why?
|
| Quality Indicators, Health Care | 3 | 2025 | 219 | 0.760 |
Why?
|
| Feedback | 1 | 2022 | 164 | 0.750 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 305 | 0.740 |
Why?
|
| Ileostomy | 1 | 2021 | 31 | 0.730 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 27 | 0.720 |
Why?
|
| Diuretics | 1 | 2021 | 171 | 0.670 |
Why?
|
| Incidence | 15 | 2023 | 3138 | 0.660 |
Why?
|
| Disease Progression | 11 | 2022 | 2058 | 0.660 |
Why?
|
| Angina Pectoris | 2 | 2016 | 57 | 0.650 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 87 | 0.630 |
Why?
|
| Coronary Artery Disease | 4 | 2022 | 790 | 0.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 732 | 0.620 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 224 | 0.610 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1327 | 0.590 |
Why?
|
| Models, Theoretical | 3 | 2019 | 359 | 0.580 |
Why?
|
| Arteriovenous Shunt, Surgical | 5 | 2017 | 101 | 0.570 |
Why?
|
| Aftercare | 2 | 2023 | 147 | 0.570 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 312 | 0.570 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 53 | 0.570 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 292 | 0.560 |
Why?
|
| Urination | 1 | 2016 | 23 | 0.540 |
Why?
|
| Diabetes Mellitus | 5 | 2024 | 872 | 0.540 |
Why?
|
| Mortality | 6 | 2021 | 238 | 0.530 |
Why?
|
| Comorbidity | 9 | 2018 | 1532 | 0.530 |
Why?
|
| Communication | 1 | 2020 | 517 | 0.520 |
Why?
|
| Peptide Fragments | 1 | 2020 | 779 | 0.510 |
Why?
|
| Disease Management | 1 | 2020 | 525 | 0.510 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 199 | 0.490 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 131 | 0.490 |
Why?
|
| Adult | 36 | 2025 | 29562 | 0.470 |
Why?
|
| Mandibular Advancement | 1 | 2014 | 6 | 0.470 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 334 | 0.470 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 2902 | 0.460 |
Why?
|
| Retrospective Studies | 30 | 2025 | 16336 | 0.460 |
Why?
|
| Albuminuria | 5 | 2019 | 99 | 0.450 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 516 | 0.440 |
Why?
|
| Myocardial Infarction | 4 | 2020 | 1018 | 0.440 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2021 | 128 | 0.440 |
Why?
|
| Polyuria | 1 | 2013 | 11 | 0.420 |
Why?
|
| Arthritis, Reactive | 1 | 2013 | 4 | 0.420 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 639 | 0.420 |
Why?
|
| Vertebral Artery | 1 | 2013 | 23 | 0.420 |
Why?
|
| Intensive Care Units | 6 | 2025 | 490 | 0.410 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 40 | 0.410 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 41 | 0.410 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 101 | 0.410 |
Why?
|
| Quality of Life | 3 | 2018 | 1943 | 0.400 |
Why?
|
| Hyponatremia | 1 | 2013 | 72 | 0.390 |
Why?
|
| Veterans Health | 1 | 2014 | 176 | 0.390 |
Why?
|
| Critical Care | 2 | 2020 | 656 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 729 | 0.390 |
Why?
|
| Time Factors | 17 | 2023 | 6319 | 0.390 |
Why?
|
| Patient Admission | 3 | 2020 | 186 | 0.390 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 664 | 0.380 |
Why?
|
| Canada | 10 | 2020 | 287 | 0.380 |
Why?
|
| Hypertension | 3 | 2015 | 1324 | 0.380 |
Why?
|
| Renal Insufficiency | 3 | 2025 | 237 | 0.370 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 57 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 207 | 0.360 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 205 | 0.360 |
Why?
|
| Length of Stay | 5 | 2025 | 1311 | 0.360 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 215 | 0.360 |
Why?
|
| Qualitative Research | 4 | 2024 | 543 | 0.350 |
Why?
|
| Treatment Outcome | 16 | 2020 | 12398 | 0.350 |
Why?
|
| Health Care Costs | 4 | 2017 | 371 | 0.350 |
Why?
|
| Societies, Medical | 2 | 2018 | 695 | 0.340 |
Why?
|
| Patient Discharge | 4 | 2025 | 490 | 0.330 |
Why?
|
| Propensity Score | 4 | 2021 | 216 | 0.330 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3287 | 0.330 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 659 | 0.330 |
Why?
|
| Kidney Function Tests | 6 | 2021 | 126 | 0.330 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 88 | 0.290 |
Why?
|
| Odds Ratio | 5 | 2021 | 1257 | 0.290 |
Why?
|
| Survival Analysis | 5 | 2020 | 1507 | 0.280 |
Why?
|
| Conservative Treatment | 2 | 2018 | 35 | 0.280 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 154 | 0.270 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 119 | 0.270 |
Why?
|
| Sick Leave | 2 | 2023 | 5 | 0.270 |
Why?
|
| Rural Health Services | 2 | 2017 | 26 | 0.260 |
Why?
|
| Recovery of Function | 4 | 2023 | 443 | 0.260 |
Why?
|
| Depression | 1 | 2014 | 1236 | 0.260 |
Why?
|
| Focus Groups | 3 | 2024 | 199 | 0.250 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 2154 | 0.250 |
Why?
|
| Fibrosis | 2 | 2018 | 429 | 0.250 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 5163 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2096 | 0.240 |
Why?
|
| Hospitals | 3 | 2023 | 388 | 0.220 |
Why?
|
| Critical Illness | 3 | 2025 | 602 | 0.220 |
Why?
|
| Fee-for-Service Plans | 1 | 2023 | 18 | 0.220 |
Why?
|
| Bacteremia | 1 | 2008 | 407 | 0.220 |
Why?
|
| Nephrologists | 1 | 2023 | 13 | 0.220 |
Why?
|
| Health Personnel | 3 | 2024 | 504 | 0.220 |
Why?
|
| Global Health | 3 | 2018 | 561 | 0.210 |
Why?
|
| Stroke | 3 | 2023 | 987 | 0.210 |
Why?
|
| Caregivers | 2 | 2019 | 575 | 0.210 |
Why?
|
| Acute Disease | 2 | 2019 | 1108 | 0.210 |
Why?
|
| Vascular Access Devices | 2 | 2013 | 35 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 17 | 0.200 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 1358 | 0.200 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 59 | 0.200 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 24 | 0.190 |
Why?
|
| Perioperative Care | 2 | 2021 | 195 | 0.190 |
Why?
|
| Age Factors | 5 | 2021 | 2822 | 0.190 |
Why?
|
| Medical Overuse | 1 | 2021 | 25 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2428 | 0.180 |
Why?
|
| Hypoglycemia | 1 | 2022 | 190 | 0.180 |
Why?
|
| Referral and Consultation | 3 | 2022 | 540 | 0.180 |
Why?
|
| Selection Bias | 1 | 2021 | 22 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2023 | 262 | 0.180 |
Why?
|
| Research Design | 2 | 2025 | 693 | 0.180 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 18 | 0.180 |
Why?
|
| Population Dynamics | 1 | 2020 | 31 | 0.170 |
Why?
|
| Warfarin | 2 | 2023 | 119 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2022 | 117 | 0.170 |
Why?
|
| Bias | 1 | 2021 | 131 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 351 | 0.170 |
Why?
|
| Air Pollution | 1 | 2020 | 66 | 0.170 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 48 | 0.160 |
Why?
|
| Physicians | 2 | 2023 | 581 | 0.160 |
Why?
|
| Registries | 4 | 2019 | 1430 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 74 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 375 | 0.160 |
Why?
|
| Coronary Disease | 2 | 2014 | 674 | 0.160 |
Why?
|
| Patient Selection | 2 | 2014 | 696 | 0.160 |
Why?
|
| Neprilysin | 1 | 2018 | 19 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2020 | 78 | 0.150 |
Why?
|
| Valsartan | 1 | 2018 | 26 | 0.150 |
Why?
|
| Aminobutyrates | 1 | 2018 | 9 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 224 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2020 | 179 | 0.150 |
Why?
|
| Heart Failure | 4 | 2017 | 2285 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 56 | 0.150 |
Why?
|
| Curcumin | 1 | 2018 | 41 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2020 | 220 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2018 | 68 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 220 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 225 | 0.150 |
Why?
|
| Risk | 3 | 2019 | 754 | 0.150 |
Why?
|
| Colonoscopy | 1 | 2020 | 236 | 0.140 |
Why?
|
| Health Status | 2 | 2018 | 376 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 192 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 266 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 174 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2018 | 112 | 0.140 |
Why?
|
| Self-Management | 1 | 2019 | 100 | 0.140 |
Why?
|
| Gadolinium | 1 | 2018 | 106 | 0.140 |
Why?
|
| Survivors | 2 | 2023 | 334 | 0.140 |
Why?
|
| Medicine | 1 | 2018 | 97 | 0.140 |
Why?
|
| Health Services, Indigenous | 1 | 2017 | 5 | 0.140 |
Why?
|
| Elective Surgical Procedures | 2 | 2018 | 160 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 3728 | 0.140 |
Why?
|
| Indians, North American | 1 | 2017 | 58 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2023 | 770 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2018 | 163 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 430 | 0.140 |
Why?
|
| Algorithms | 1 | 2023 | 1624 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1024 | 0.130 |
Why?
|
| Pyrenes | 1 | 2016 | 5 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2023 | 592 | 0.130 |
Why?
|
| Health Resources | 1 | 2017 | 116 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2020 | 1179 | 0.130 |
Why?
|
| Urban Health Services | 1 | 2016 | 22 | 0.130 |
Why?
|
| Catheterization | 1 | 2017 | 234 | 0.130 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 128 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2019 | 443 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 74 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2881 | 0.120 |
Why?
|
| Income | 1 | 2016 | 133 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2018 | 209 | 0.120 |
Why?
|
| Lymphoma | 1 | 2018 | 322 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 161 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 641 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 156 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 73 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1182 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 442 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2015 | 77 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 246 | 0.110 |
Why?
|
| Young Adult | 4 | 2021 | 9047 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 278 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2015 | 249 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2023 | 1190 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2017 | 542 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 449 | 0.100 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 53 | 0.100 |
Why?
|
| Publication Bias | 1 | 2013 | 14 | 0.100 |
Why?
|
| Oxygen | 1 | 2015 | 553 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 65 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 232 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 820 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 635 | 0.090 |
Why?
|
| Mass Screening | 1 | 2017 | 783 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 432 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2013 | 186 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2010 | 50 | 0.090 |
Why?
|
| Creatine | 1 | 2010 | 41 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 607 | 0.090 |
Why?
|
| Information Services | 1 | 2009 | 21 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 931 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 569 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2022 | 213 | 0.080 |
Why?
|
| Ontario | 2 | 2023 | 64 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 78 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 176 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 806 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1314 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2051 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 139 | 0.070 |
Why?
|
| Logistic Models | 3 | 2020 | 1811 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1884 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2013 | 6148 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 51 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2023 | 468 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 44 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2060 | 0.070 |
Why?
|
| Adolescent | 2 | 2021 | 19336 | 0.060 |
Why?
|
| Biomarkers | 4 | 2018 | 3069 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2023 | 388 | 0.060 |
Why?
|
| Anemia | 1 | 2009 | 339 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 364 | 0.060 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 221 | 0.060 |
Why?
|
| Obesity | 1 | 2015 | 2237 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2025 | 332 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 509 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 649 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2022 | 11 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 84 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 123 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2016 | 309 | 0.050 |
Why?
|
| Exercise Test | 1 | 2022 | 254 | 0.050 |
Why?
|
| Patient Preference | 1 | 2022 | 119 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 18 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 76 | 0.040 |
Why?
|
| Health Planning | 1 | 2020 | 15 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 65 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 69 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 315 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 645 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 317 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 276 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 14 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 2448 | 0.040 |
Why?
|
| United States | 2 | 2013 | 10906 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 38 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 61 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1137 | 0.040 |
Why?
|
| Telemedicine | 1 | 2024 | 435 | 0.040 |
Why?
|
| Radiologists | 1 | 2018 | 45 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 15 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 570 | 0.040 |
Why?
|
| Australasia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Catheter Obstruction | 1 | 2017 | 8 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1692 | 0.040 |
Why?
|
| Manitoba | 1 | 2017 | 3 | 0.040 |
Why?
|
| Aviation | 1 | 2017 | 5 | 0.040 |
Why?
|
| Motor Vehicles | 1 | 2017 | 9 | 0.040 |
Why?
|
| Decision Making | 1 | 2022 | 656 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 51 | 0.030 |
Why?
|
| Affect | 1 | 2018 | 158 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 27 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 101 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 84 | 0.030 |
Why?
|
| North America | 1 | 2017 | 240 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 111 | 0.030 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2016 | 9 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 682 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 181 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 353 | 0.030 |
Why?
|
| Palliative Care | 1 | 2020 | 429 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 315 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 428 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 29 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 345 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 360 | 0.030 |
Why?
|
| Emergencies | 1 | 2016 | 172 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 177 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1642 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 590 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 146 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 221 | 0.030 |
Why?
|
| Premedication | 1 | 2014 | 42 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 830 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 646 | 0.030 |
Why?
|
| Wrist Injuries | 1 | 2013 | 6 | 0.030 |
Why?
|
| British Columbia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 42 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 2013 | 39 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 242 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 78 | 0.030 |
Why?
|
| United Kingdom | 1 | 2013 | 190 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 285 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2013 | 61 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 462 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1088 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1439 | 0.020 |
Why?
|
| Thrombosis | 1 | 2017 | 522 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1240 | 0.020 |
Why?
|
| Reagent Strips | 1 | 2011 | 11 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 436 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 178 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 726 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 267 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 121 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 141 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 228 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1116 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 589 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 371 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 181 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 253 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 865 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 142 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1420 | 0.020 |
Why?
|
| Patient Safety | 1 | 2013 | 401 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 34046 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 288 | 0.020 |
Why?
|
| Child | 1 | 2022 | 24399 | 0.010 |
Why?
|